{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:34:08Z","timestamp":1788950048081,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Liaoning Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2021-MS-196"],"award-info":[{"award-number":["2021-MS-196"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Liaoning Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023-MS-051"],"award-info":[{"award-number":["2023-MS-051"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Liaoning Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["22-321-33-47"],"award-info":[{"award-number":["22-321-33-47"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clgc.2024.102211","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T01:04:55Z","timestamp":1724461495000},"page":"102211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Markers in Identifying Pathological Complete Response Status in Muscle Invasive Bladder Cancer Patients Who Achieved Clinical Complete Response After Neoadjuvant Chemotherapy"],"prefix":"10.1016","volume":"22","author":[{"given":"Chengri","family":"Piao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4835-6140","authenticated-orcid":false,"given":"Liping","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2024.102211_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clgc.2024.102211_bib0002","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clgc.2024.102211_bib0003","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102211_bib0004","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.eururo.2014.11.043","article-title":"Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial","volume":"67","author":"Bochner","year":"2015","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102211_bib0005","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2024.102211_bib0006","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1097\/PAS.0000000000001371","article-title":"Multicenter validation of histopathologic tumor regression grade after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma","volume":"43","author":"Voskuilen","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102211_bib0007","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3233\/BLC-170134","article-title":"Systematic review and meta-analysis on the efficacy of chemotherapy with transurethral resection of bladder tumors as definitive therapy for muscle invasive bladder cancer","volume":"3","author":"Moran","year":"2017","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.102211_bib0008","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.urology.2014.03.040","article-title":"The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer","volume":"84","author":"Reese","year":"2014","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.clgc.2024.102211_bib0009","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/JU.0000000000001602","article-title":"Cystoscopy and Systematic bladder tissue sampling in predicting pt0 bladder cancer: a prospective trial","volume":"205","author":"Zibelman","year":"2021","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102211_bib0010","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.juro.2014.03.078","article-title":"The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder","volume":"192","author":"Meyer","year":"2014","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102211_bib0011","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"2","key":"10.1016\/j.clgc.2024.102211_bib0012","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00345-013-1128-x","article-title":"The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer","volume":"32","author":"Kim","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2024.102211_bib0013","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11255-016-1491-9","article-title":"WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach","volume":"49","author":"Otto","year":"2017","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102211_bib0014","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","article-title":"Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study","volume":"200","author":"Mazza","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102211_bib0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.euros.2022.05.001","article-title":"The impact of primary versus secondary muscle-invasive bladder cancer at diagnosis on the response to neoadjuvant chemotherapy","volume":"41","author":"D'Andrea","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"10.1016\/j.clgc.2024.102211_bib0016","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102211_bib0017","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clgc.2015.09.013","article-title":"Predictors of complete pathologic response (pt0) to neoadjuvant chemotherapy in muscle-invasive bladder carcinoma","volume":"14","author":"Pokuri","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2024.102211_bib0018","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102211_bib0019","series-title":"EAU guidelines published at the 38th Annual Congress Milan","article-title":"EAU guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS)","author":"Gontero","year":"2023"},{"issue":"1","key":"10.1016\/j.clgc.2024.102211_bib0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.juro.2018.05.162","article-title":"Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: a systematic review and meta-analysis","volume":"201","author":"Kimura","year":"2019","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.clgc.2024.102211_bib0021","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.urolonc.2014.05.008","article-title":"Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: a systematic review and meta-analysis","volume":"32","author":"Kim","year":"2014","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102211_bib0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.14417","article-title":"A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens","volume":"123","author":"Mari","year":"2019","journal-title":"BJU Int"},{"issue":"8","key":"10.1016\/j.clgc.2024.102211_bib0023","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrurol.2016.126","article-title":"The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder","volume":"13","author":"Mathieu","year":"2016","journal-title":"Nat Rev Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:31:01Z","timestamp":1762551061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1558767324001812"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102211","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Markers in Identifying Pathological Complete Response Status in Muscle Invasive Bladder Cancer Patients Who Achieved Clinical Complete Response After Neoadjuvant Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102211"}}